Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track INO with free AI briefings, catalyst countdowns, and dilution alerts.

INO · INOVIO PHARMACEUTICALS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$139.8M Cash, Pro Forma
25.2mo Cash Runway
22.1% Short Interest
$6.33 Analyst Target (3)
Follow INO by email Get an email when INO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about INO, unsubscribe in one click. Privacy

📣 What INO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Reluscovtogene Ralaplasmid (INO-4800) Coronavirus Infection Phase 2/3 · NCT04642638 Terminated
Bizalimogene Ralaplasmid (VGX-3100) Cervical Dysplasia Phase 3 · NCT03721978 Completed
DNA Plasmid-encoding Interleukin-12/HPV DNA… Uterine Cervical Neoplasms Phase 2 · NCT02501278 Withdrawn
HPV6/11-targeted DNA Plasmid Vaccine INO-3107 Respiratory Papillomatosis Phase 1/2 · NCT04398433 Completed
p.DOM-WT1-37 DNA Vaccine Leukaemia (Acute) Phase 2 · NCT01334060 Completed
Human Immunodeficiency Virus DNA HIV-1-infection Phase 1/2 · NCT03606213 Completed
Imiquimod 5% Cream Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) Phase 2 · NCT03180684 Completed
Rocakinogene Sifuplasmid (INO-9012) Glioblastoma Phase 1/2 · NCT03491683 Active not recruiting
GLS-5300 Healthy Phase 1/2 · NCT03721718 Completed
WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401 Glioblastoma Phase 1/2 · NCT03491683 Active not recruiting
Cisplatin chemotherapy Uterine Cervical Neoplasms Phase 2 · NCT02501278 Withdrawn
INO-4700 Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Phase 2 · NCT04588428 Completed
INO-4500 Lassa Fever Phase 1 · NCT04093076 Completed
INO-9112 Coronavirus Infection Phase 1 · NCT05430958 Withdrawn
DNA Plasmid-encoding Interleukin-12… Metastatic Castration-resistant Prostate Cancer Phase 1 · NCT03835533 Completed
INO-A002 Healthy Volunteers Phase 1 · NCT03831503 Completed

Also used in these trials (approved or third-party drugs, not INO's own candidates): Temozolomide, Cemiplimab, Atezolizumab, Nivolumab, Poly ICLC, Alum.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

INO had $48.4M in cash and short-term investments on its Sep 30, 2026 balance sheet. Including the cash events since then, it holds about $139.8M pro forma, before operating spending after that date:

It burns about $16.7M/quarter from operations, an estimated runway of 25.2 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 60 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INO files for a raise →

👥 Who Owns INO

Insiders 0.2% Other 5%+ holders 9.6% Institutions 43.5% Public and other holders 46.7%
HolderTypeShares% of sharesAs of
Highbridge Capital Management, LLC Institution (13G, 5%+) 25,288,217 13.50% 2026-09-30
TANG CAPITAL MANAGEMENT, LLC 5%+ holder (13G) 17,978,200 9.60% 2026-11-06
FMR LLC Institution (13G, 5%+) 15,364,105 8.20% 2026-09-30
RA Capital Management, L.P. Institution (13G, 5%+) 10,666,523 5.69% 2026-07-31
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 6,666,295 3.56% 2025-11-28
ADAR1 Capital Management, LLC Institution (13G, 5%+) 6,429,624 3.43% 2026-06-30
Vanguard Capital Management Institution (13G, 5%+) 4,161,566 2.22% 2026-06-30
Citadel Advisors Llc Institution (13F) 3,126,541 1.67% 2026-09-30
Two Sigma Investments, LP Institution (13F) 2,539,360 1.36% 2026-09-30
Shaw D.E. & Co., Inc. Institution (13F) 2,468,480 1.32% 2026-09-30
Marshall Wace LLP Institution (13F) 2,279,039 1.22% 2026-09-30
Renaissance Technologies, LLC Institution (13F) 1,513,187 0.81% 2026-09-30

Share count 187,306,884 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-05-20
filed 2026-05-21
BENITO SIMON X
Option award (A) 41,800 – –
2026-05-20
filed 2026-05-21
DANSEY ROGER D
Option award (A) 41,800 – –
2026-05-20
filed 2026-05-21
Weiner David B.
Option award (A) 34,200 – –
2026-05-20
filed 2026-05-21
Weiner David B.
Option award (A) 41,800 – –
2026-05-20
filed 2026-05-21
Shepard Jay
Option award (A) 34,200 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-10-30 VOCERYQ BLA -36.9% -22.1% —
2025-05-13 — BLA +22.8% -1% +6.7%

Browse all historical PDUFA outcomes →

Get the full INO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.